Regulation of steroid 5-α reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin

Young Kyo Seo, Bing Zhu, Tae Il Jeon, Timothy F. Osborne

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In this study, we show that sterol regulatory element binding proteins (SREBPs) regulate expression of Srd5a2, an enzyme that catalyzes the irreversible conversion of testosterone to dihydroxytestosterone in the male reproductive tract and is highly expressed in androgen-sensitive tissues such as the prostate and skin. We show that Srd5a2 is induced in livers and prostate from mice fed a chow diet supplemented with lovastatin plus ezitimibe (L/E), which increases the activity of nuclear SREBP-2. The three fold increase in Srd5a2 mRNA mediated by L/E treatment was accompanied by the induction of SREBP-2 binding to the Srd5a2 promoter detected by a ChIP-chip assay in liver. We identified a SREBP-2 responsive region within the first 300 upstream bases of the mouse Srd5a2 promoter by co-transfection assays which contain a site that bound SREBP-2 in vitro by an EMSA. Srd5a2 protein was also induced in cells over-expressing SREBP-2 in culture. The induction of Srd5a2 through SREBP-2 provides a mechanistic explanation for why even though statin therapy is effective in reducing cholesterol levels in treating hypercholesterolemia it does not compromise androgen production in clinical studies.

Original languageEnglish (US)
Pages (from-to)3133-3139
Number of pages7
JournalExperimental Cell Research
Volume315
Issue number18
DOIs
StatePublished - Nov 1 2009

Fingerprint

Sterol Regulatory Element Binding Protein 2
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Oxidoreductases
Steroids
Lovastatin
Androgens
Prostate
Sterol Regulatory Element Binding Proteins
Liver
Hypercholesterolemia
Protein Binding
Transfection
Testosterone
Cholesterol
Diet
Messenger RNA
Skin

Keywords

  • Androgen regulation
  • ChIP-chip assay
  • Srd5a2
  • SREBP-2
  • Statin
  • Transcription regulation

ASJC Scopus subject areas

  • Cell Biology

Cite this

Regulation of steroid 5-α reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin. / Seo, Young Kyo; Zhu, Bing; Jeon, Tae Il; Osborne, Timothy F.

In: Experimental Cell Research, Vol. 315, No. 18, 01.11.2009, p. 3133-3139.

Research output: Contribution to journalArticle

Seo, Young Kyo ; Zhu, Bing ; Jeon, Tae Il ; Osborne, Timothy F. / Regulation of steroid 5-α reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin. In: Experimental Cell Research. 2009 ; Vol. 315, No. 18. pp. 3133-3139.
@article{88651362251a4577b335e760d6400352,
title = "Regulation of steroid 5-α reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin",
abstract = "In this study, we show that sterol regulatory element binding proteins (SREBPs) regulate expression of Srd5a2, an enzyme that catalyzes the irreversible conversion of testosterone to dihydroxytestosterone in the male reproductive tract and is highly expressed in androgen-sensitive tissues such as the prostate and skin. We show that Srd5a2 is induced in livers and prostate from mice fed a chow diet supplemented with lovastatin plus ezitimibe (L/E), which increases the activity of nuclear SREBP-2. The three fold increase in Srd5a2 mRNA mediated by L/E treatment was accompanied by the induction of SREBP-2 binding to the Srd5a2 promoter detected by a ChIP-chip assay in liver. We identified a SREBP-2 responsive region within the first 300 upstream bases of the mouse Srd5a2 promoter by co-transfection assays which contain a site that bound SREBP-2 in vitro by an EMSA. Srd5a2 protein was also induced in cells over-expressing SREBP-2 in culture. The induction of Srd5a2 through SREBP-2 provides a mechanistic explanation for why even though statin therapy is effective in reducing cholesterol levels in treating hypercholesterolemia it does not compromise androgen production in clinical studies.",
keywords = "Androgen regulation, ChIP-chip assay, Srd5a2, SREBP-2, Statin, Transcription regulation",
author = "Seo, {Young Kyo} and Bing Zhu and Jeon, {Tae Il} and Osborne, {Timothy F.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1016/j.yexcr.2009.05.025",
language = "English (US)",
volume = "315",
pages = "3133--3139",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "18",

}

TY - JOUR

T1 - Regulation of steroid 5-α reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin

AU - Seo, Young Kyo

AU - Zhu, Bing

AU - Jeon, Tae Il

AU - Osborne, Timothy F.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - In this study, we show that sterol regulatory element binding proteins (SREBPs) regulate expression of Srd5a2, an enzyme that catalyzes the irreversible conversion of testosterone to dihydroxytestosterone in the male reproductive tract and is highly expressed in androgen-sensitive tissues such as the prostate and skin. We show that Srd5a2 is induced in livers and prostate from mice fed a chow diet supplemented with lovastatin plus ezitimibe (L/E), which increases the activity of nuclear SREBP-2. The three fold increase in Srd5a2 mRNA mediated by L/E treatment was accompanied by the induction of SREBP-2 binding to the Srd5a2 promoter detected by a ChIP-chip assay in liver. We identified a SREBP-2 responsive region within the first 300 upstream bases of the mouse Srd5a2 promoter by co-transfection assays which contain a site that bound SREBP-2 in vitro by an EMSA. Srd5a2 protein was also induced in cells over-expressing SREBP-2 in culture. The induction of Srd5a2 through SREBP-2 provides a mechanistic explanation for why even though statin therapy is effective in reducing cholesterol levels in treating hypercholesterolemia it does not compromise androgen production in clinical studies.

AB - In this study, we show that sterol regulatory element binding proteins (SREBPs) regulate expression of Srd5a2, an enzyme that catalyzes the irreversible conversion of testosterone to dihydroxytestosterone in the male reproductive tract and is highly expressed in androgen-sensitive tissues such as the prostate and skin. We show that Srd5a2 is induced in livers and prostate from mice fed a chow diet supplemented with lovastatin plus ezitimibe (L/E), which increases the activity of nuclear SREBP-2. The three fold increase in Srd5a2 mRNA mediated by L/E treatment was accompanied by the induction of SREBP-2 binding to the Srd5a2 promoter detected by a ChIP-chip assay in liver. We identified a SREBP-2 responsive region within the first 300 upstream bases of the mouse Srd5a2 promoter by co-transfection assays which contain a site that bound SREBP-2 in vitro by an EMSA. Srd5a2 protein was also induced in cells over-expressing SREBP-2 in culture. The induction of Srd5a2 through SREBP-2 provides a mechanistic explanation for why even though statin therapy is effective in reducing cholesterol levels in treating hypercholesterolemia it does not compromise androgen production in clinical studies.

KW - Androgen regulation

KW - ChIP-chip assay

KW - Srd5a2

KW - SREBP-2

KW - Statin

KW - Transcription regulation

UR - http://www.scopus.com/inward/record.url?scp=70349909669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349909669&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2009.05.025

DO - 10.1016/j.yexcr.2009.05.025

M3 - Article

C2 - 19500568

AN - SCOPUS:70349909669

VL - 315

SP - 3133

EP - 3139

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 18

ER -